Contra-indicated in patients with uncontrolled hypertension.
This drug has been recalled.
- TRADE NAME: Omontys (Affymax)
- INDICATIONS: Anemia due to chronic kidney disease in adult patients on dialysis
- CLASS: Erythropoiesis-stimulating agent (ESA)
- HALF-LIFE: 17–33 hours (following intravenous administration)
- FDA APPROVAL DATE: 03/27/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of peginesatide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
